Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials

Clinical trial results indicate that brentuximab vedotin brings considerable promise for the treatment of patients with relapsed or refractory Hodgkin’s lymphoma. A retrospective multicenter study was conducted on 65 heavily pretreated patients who underwent therapy through a Named Patient Program i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Zinzani, Pier Luigi, Viviani, Simonetta, Anastasia, Antonella, Vitolo, Umberto, Luminari, Stefano, Zaja, Francesco, Corradini, Paolo, Spina, Michele, Brusamolino, Ercole, Gianni, Alessandro M., Santoro, Armando, Botto, Barbara, Derenzini, Enrico, Pellegrini, Cinzia, Argnani, Lisa
Natura: Artigo
Lingua:Inglês
Pubblicazione: Ferrata Storti Foundation 2013
Soggetti:
Original Articles and Brief Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3729903/
https://ncbi.nlm.nih.gov/pubmed/23645687
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.083048
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi